Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
Invivyd, Inc. (IVVD)
Company Research
Source: GlobeNewswire
Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19 Initial data readouts from Phase 1 VYD222 clinical trial planned for Q2 with additional clinical readouts from the VYD222 program anticipated in 2023 Published landmark clinical research in Science Translational Medicine that provides strong scientific rationale for using surrogate endpoints to expedite clinical development of mAbs for the prevention of symptomatic COVID-19 Well capitalized with $333.4 million in cash, cash equivalents and marketable securities expected to support operating runway into second half of 2024 excluding potential contribution of commercial product revenue Conference call scheduled for Thursday, May 11th at 4:30 p.m. ET WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to prot
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™GlobeNewswire
- Invivyd Announces CEO TransitionGlobeNewswire
- We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Invivyd, Inc. (NASDAQ: IVVD) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $9.00 price target on the stock.MarketBeat
- Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million [Yahoo! Finance]Yahoo! Finance
IVVD
Earnings
- 11/9/23 - Beat
IVVD
Sec Filings
- 4/18/24 - Form ARS
- 4/18/24 - Form DEF
- 4/12/24 - Form 8-K
- IVVD's page on the SEC website